Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study

Marco Zecca, Robert Wynn, Jean Hugues Dalle, Tobias Feuchtinger, Enrikas Vainorius, Thomas M. Brundage, Aastha Chandak, Essy Mozaffari, Garrett Nichols, Franco Locatelli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

This multivariable analysis from the AdVance multicenter observational study assessed adenovirus (AdV) viremia peak, duration, and overall AdV viral burden—measured as time-averaged area under the viremia curve over 16 weeks (AAUC 0-16 )—as predictors of all-cause mortality in pediatric allo-HCT recipients with AdV viremia. In the 6 months following allo-HCT, 241 patients had AdV viremia ≥ 1000 copies/ml. Among these, 18% (43/241) died within 6 months of first AdV ≥ 1000 copies/ml. Measures of AdV viral peak, duration, and overall burden of infection consistently correlate with all-cause mortality. In multivariable analyses, controlling for lymphocyte recovery, patients with AdV AAUC 0-16 in the highest quartile had a hazard ratio of 11.1 versus the lowest quartile (confidence interval 5.3–23.6); for peak AdV viremia, the hazard ratio was 2.2 for the highest versus lowest quartile. Both the peak level and duration of AdV viremia were correlated with short-term mortality, independent of other known risk factors for AdV-related mortality, such as lymphocyte recovery. AdV AAUC 0-16 , which assesses both peak and duration of AdV viremia, is highly correlated with mortality under the current standard of care. New therapeutic agents that decrease AdV AAUC 0-16 have the potential of reducing mortality in this at-risk patient population.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Viral Load
Adenoviridae
Pediatrics
Viremia
Mortality
Lymphocytes
Standard of Care
Multicenter Studies
Area Under Curve
Observational Studies
Confidence Intervals

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Association between adenovirus viral load and mortality in pediatric allo-HCT recipients : the multinational AdVance study. / Zecca, Marco; Wynn, Robert; Dalle, Jean Hugues; Feuchtinger, Tobias; Vainorius, Enrikas; Brundage, Thomas M.; Chandak, Aastha; Mozaffari, Essy; Nichols, Garrett; Locatelli, Franco.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Zecca, Marco ; Wynn, Robert ; Dalle, Jean Hugues ; Feuchtinger, Tobias ; Vainorius, Enrikas ; Brundage, Thomas M. ; Chandak, Aastha ; Mozaffari, Essy ; Nichols, Garrett ; Locatelli, Franco. / Association between adenovirus viral load and mortality in pediatric allo-HCT recipients : the multinational AdVance study. In: Bone Marrow Transplantation. 2019.
@article{bf66de47cb1f4f35a66670d0b0182f47,
title = "Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study",
abstract = "This multivariable analysis from the AdVance multicenter observational study assessed adenovirus (AdV) viremia peak, duration, and overall AdV viral burden—measured as time-averaged area under the viremia curve over 16 weeks (AAUC 0-16 )—as predictors of all-cause mortality in pediatric allo-HCT recipients with AdV viremia. In the 6 months following allo-HCT, 241 patients had AdV viremia ≥ 1000 copies/ml. Among these, 18{\%} (43/241) died within 6 months of first AdV ≥ 1000 copies/ml. Measures of AdV viral peak, duration, and overall burden of infection consistently correlate with all-cause mortality. In multivariable analyses, controlling for lymphocyte recovery, patients with AdV AAUC 0-16 in the highest quartile had a hazard ratio of 11.1 versus the lowest quartile (confidence interval 5.3–23.6); for peak AdV viremia, the hazard ratio was 2.2 for the highest versus lowest quartile. Both the peak level and duration of AdV viremia were correlated with short-term mortality, independent of other known risk factors for AdV-related mortality, such as lymphocyte recovery. AdV AAUC 0-16 , which assesses both peak and duration of AdV viremia, is highly correlated with mortality under the current standard of care. New therapeutic agents that decrease AdV AAUC 0-16 have the potential of reducing mortality in this at-risk patient population.",
author = "Marco Zecca and Robert Wynn and Dalle, {Jean Hugues} and Tobias Feuchtinger and Enrikas Vainorius and Brundage, {Thomas M.} and Aastha Chandak and Essy Mozaffari and Garrett Nichols and Franco Locatelli",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0483-7",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Association between adenovirus viral load and mortality in pediatric allo-HCT recipients

T2 - the multinational AdVance study

AU - Zecca, Marco

AU - Wynn, Robert

AU - Dalle, Jean Hugues

AU - Feuchtinger, Tobias

AU - Vainorius, Enrikas

AU - Brundage, Thomas M.

AU - Chandak, Aastha

AU - Mozaffari, Essy

AU - Nichols, Garrett

AU - Locatelli, Franco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - This multivariable analysis from the AdVance multicenter observational study assessed adenovirus (AdV) viremia peak, duration, and overall AdV viral burden—measured as time-averaged area under the viremia curve over 16 weeks (AAUC 0-16 )—as predictors of all-cause mortality in pediatric allo-HCT recipients with AdV viremia. In the 6 months following allo-HCT, 241 patients had AdV viremia ≥ 1000 copies/ml. Among these, 18% (43/241) died within 6 months of first AdV ≥ 1000 copies/ml. Measures of AdV viral peak, duration, and overall burden of infection consistently correlate with all-cause mortality. In multivariable analyses, controlling for lymphocyte recovery, patients with AdV AAUC 0-16 in the highest quartile had a hazard ratio of 11.1 versus the lowest quartile (confidence interval 5.3–23.6); for peak AdV viremia, the hazard ratio was 2.2 for the highest versus lowest quartile. Both the peak level and duration of AdV viremia were correlated with short-term mortality, independent of other known risk factors for AdV-related mortality, such as lymphocyte recovery. AdV AAUC 0-16 , which assesses both peak and duration of AdV viremia, is highly correlated with mortality under the current standard of care. New therapeutic agents that decrease AdV AAUC 0-16 have the potential of reducing mortality in this at-risk patient population.

AB - This multivariable analysis from the AdVance multicenter observational study assessed adenovirus (AdV) viremia peak, duration, and overall AdV viral burden—measured as time-averaged area under the viremia curve over 16 weeks (AAUC 0-16 )—as predictors of all-cause mortality in pediatric allo-HCT recipients with AdV viremia. In the 6 months following allo-HCT, 241 patients had AdV viremia ≥ 1000 copies/ml. Among these, 18% (43/241) died within 6 months of first AdV ≥ 1000 copies/ml. Measures of AdV viral peak, duration, and overall burden of infection consistently correlate with all-cause mortality. In multivariable analyses, controlling for lymphocyte recovery, patients with AdV AAUC 0-16 in the highest quartile had a hazard ratio of 11.1 versus the lowest quartile (confidence interval 5.3–23.6); for peak AdV viremia, the hazard ratio was 2.2 for the highest versus lowest quartile. Both the peak level and duration of AdV viremia were correlated with short-term mortality, independent of other known risk factors for AdV-related mortality, such as lymphocyte recovery. AdV AAUC 0-16 , which assesses both peak and duration of AdV viremia, is highly correlated with mortality under the current standard of care. New therapeutic agents that decrease AdV AAUC 0-16 have the potential of reducing mortality in this at-risk patient population.

UR - http://www.scopus.com/inward/record.url?scp=85062099310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062099310&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0483-7

DO - 10.1038/s41409-019-0483-7

M3 - Article

AN - SCOPUS:85062099310

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -